Similar effectiveness of dapagliflozin and GLP-1 receptor agonists concerning combined endpoints in routine clinical practice: A multicentre retrospective study.

Gian Poalo FadiniVeronica SciannameoIvano FranzettiDaniele BottigliengoPaola D'AngeloCarmela VinciPaola BerchiallaSalvatore ArenaRaffaella BuzzettiAngelo Avogaronull null

Published in: Diabetes, obesity & metabolism (2019)

In routine specialist care, initiation of dapagliflozin can be as effective as initiation of a GLP-1RA for attainment of combined risk factor goals.

Keyphrases

clinical practice
palliative care
risk factors
healthcare
randomized controlled trial
systematic review
clinical trial
rheumatoid arthritis
study protocol
quality improvement
cross sectional
global health
ankylosing spondylitis
affordable care act
systemic sclerosis
health insurance